Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer
Maturitas · 2026
DOI: 10.1016/j.maturitas.2026.108878 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Maturitas, 2026. Verfasst von Mariya O Pogorelova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States. Electronic addr…. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Antineoplastic Agents, Hormonal, Medication Adherence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Tamoxifen 20 mg daily for 5 years decreases breast cancer (BC) risk by 49% in women with a family history of the disease and by up to 85% in women with a personal history of high-risk lesions. The TAM-01 study demonstrated that patients with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) had a 50% reduction in cancer events with 5 mg daily for 3 years. We aimed to determine whether the use of low-dose tamoxifen (LDT) leads to better adherence and tolerance than standard-dose tamoxifen (SDT). STUDY DESIGN: A retrospective chart review of women with DCIS, LCIS, ADH/ALH, increased risk due to family history of breast cancer, or high-risk gene mutation was performed. Patients were grouped as SDT or LDT. Patients who declined medications were the control. RESULTS: Among 256 patients, 46% (N = 117) initiated LDT, 21% (N = 55) SDT and 33% (N = 84) declined tamoxifen. 59% of patients on LDT completed 3 years of therapy compared with 47.3% of SDT patients. Five women (2.0%) developed recurrent cancer, and 4 women (1.6%) developed a new malignancy. Vasomotor symptoms were the most commonly reported adverse events, affecting over 40% of patients in both tamoxifen groups. CONCLUSION: LDT was well tolerated, with a trend toward increased likelihood of completion of therapy. Patients with more than one indication for tamoxifen were more likely to complete therapy. Side-effects were similar in the two treatment groups, although severity was not able to be assessed due to the retrospective study design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States. Electronic address: Pogorelova.Mariya@mayo.edu.
- Department of Medicine, Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States. Electronic address: Buzzard.Jennifer@mayo.edu.
- Deparment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic,205 3rd Ave SW, Rochester, MN, 55905, United States. Electronic address: Fischer.Karen@mayo.edu.
- Department of Medicine, Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States. Electronic address: Salonen.Bradley@mayo.edu.
- Department of Medicine, Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, United States. Electronic address: Klassen.Christine@mayo.edu.
Zitieren
APA
Pogorelova, M. O., Buzzard, J. A., Fischer, K. M., Salonen, B. R., & Klassen, C. L. (2026). Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer. Maturitas. https://doi.org/10.1016/j.maturitas.2026.108878
Vancouver
Pogorelova MO, Buzzard JA, Fischer KM, Salonen BR, Klassen CL. Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer. Maturitas. 2026. doi:10.1016/j.maturitas.2026.108878
BibTeX
@article{Pogorelova2026,
author = {Pogorelova, Mariya O and Buzzard, Jennifer A and Fischer, Karen M and Salonen, Bradley R and Klassen, Christine L},
title = {Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer},
journal = {Maturitas},
year = {2026},
doi = {10.1016/j.maturitas.2026.108878}
}
EUVIMED